Fig. 3: Effect of garetosmab in period 2 relative to period 1 on the total number of new HO lesions, the mean total volume of new HO lesions, the TLA in new HO lesions and the percentages of patients with new lesions assessed by quantitative imaging in those originally randomized to placebo.

a, Total number of new lesions by CT during period 2 relative to period 1 (mITT analysis set). b, Total number of new lesions by ¹⁸F-NaF PET during period 2 relative to period 1 (mITT analysis set). c, Mean total volume of new lesions as assessed by CT in period 2 relative to period 1 (mITT analysis set). d, TLA of new lesions by 18F-NaF PET in period 2 relative to period 1 (mITT analysis set). e, Percent of patients with new lesions by CT during period 2 relative to period 1 (mITT analysis set). f, Percent of patients with new lesions by ¹⁸F-NaF PET during period 2 relative to period 1 (mITT analysis set). P values were generated from a Wilcoxon signed-rank test (a–d) and a McNemar’s test (e,f). P values were not adjusted for multiple testing; however, a hierarchical testing strategy was prespecified before analysis of the data.